Kostaras Dimitris, Karampli Eleftheria, Athanasakis Kostas
a Department of Health Economics , National School of Public Health , Athens , Greece.
b Vaccines Department , Athens , MSD Greece.
Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):147-158. doi: 10.1080/14737167.2019.1555039. Epub 2018 Dec 10.
During the last years, a significant number economic evaluations of HPV vaccination has been published. Given that cost-effectiveness constitutes an essential part of decision-making with regards to the reimbursement of a health technology, the purpose of this study is to provide a supportive tool to decision-makers regarding the economic efficiency of the introduction of HPV vaccination to national immunization programs.
The PubMed database was searched in order to identify cost-effectiveness studies for HPV vaccination. A total of 42 articles were finally retrieved. All retrieved cost-effectiveness ratios (ICERs) were converted in the same currency unit (I$) and then inflated to the same year (2015) in order to facilitate cross-country comparisons.
Overall, vaccination against HPV 6,11,16,18 types appears to have a ICER with mean value of I$25132/QALY, whereas the mean ICER of vaccination against oncogenic HPV 16,18 types is estimated at I$38,253/QALY.
HPV vaccination would be a cost-effective intervention in the setting of high-income countries and could reduce the incidence of HPV-related diseases.
在过去几年中，已发表了大量关于人乳头瘤病毒（HPV）疫苗接种的经济评估报告。鉴于成本效益是卫生技术报销决策的重要组成部分，本研究的目的是为决策者提供一个关于将HPV疫苗接种引入国家免疫规划的经济效率的支持工具。
检索了PubMed数据库，以确定HPV疫苗接种的成本效益研究。最终共检索到42篇文章。所有检索到的成本效益比（ICER）均转换为同一货币单位（国际美元），然后折算到同一年（2015年），以方便进行跨国比较。
总体而言，接种针对HPV 6、11、16、18型的疫苗，其ICER的平均值为每质量调整生命年25132国际美元，而接种针对致癌性HPV 16、18型的疫苗，其ICER的平均值估计为每质量调整生命年38253国际美元。
在高收入国家，HPV疫苗接种将是一种具有成本效益的干预措施，可降低HPV相关疾病的发病率。
